☆ 4.7 Article

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

JOURNAL OF CLINICAL ONCOLOGY (2020)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 38, Issue 15_suppl, Pages 7512-7512

Publisher

American Society of Clinical Oncology (ASCO)

DOI: 10.1200/jco.2020.38.15_suppl.7512

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.